This study investigated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes in the PARADIGM trial (n=733) of patients with RAS wild-type metastatic colorectal cancer (mCRC). Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA lacking gene alterations (median 40.7 vs 34.4 months; hazard ratio, 0.76). However, survival was similar or inferior with panitumumab in patients with ctDNA containing any alteration (19.2 vs 22.2 months; hazard ratio, 1.13). Negative hyperselection using ctDNA may guide treatment selection in mCRC.